Global Protein Therapeutics Market Analysis
Single User PDF Format: US$ 1,800.00
Multi-User License: US$ 2,800.00
Hard Copy: US$ 2,200.00
CD-ROM: US$ 2,200.00
Within the global pharmaceutical industry, protein therapeutics has been enjoying the fastest growth for the past few years. Playing a significant role in the treatment of many major diseases, protein therapies have revolutionized the methodology followed by drugs. These therapies owe their high efficiency to their targeted approach, which avoids side effects on healthy organs to a great extent. The acceptance of the various protein therapies can be attributed to the increasing prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and rising penetration of medical insurance.
According to our new research report “Global Protein Therapeutics Market Analysis”, the global protein therapeutics market is expected to grow at a CAGR of around 13% during 2012-2014. Various factors, such as introduction of new protein therapeutics and enhanced investments will contribute to the buoyant growth of this industry. Besides, augmentation in the number of clinical trials will surface the optimistic performance of the industry.
Based on our in-depth analysis of the industry, we have identified the major segments in protein therapeutics market, which include Monoclonal antibody, Insulin, Interferon, G-CSF, coagulation factors etc. Amongst the segments, monoclonal antibody dominates the global protein therapeutics market and is expected to be at the top in future as well. This has been possible due to the large numbers of players that have been directing their efforts to develop innovative treatments using mAbs.
As per our research, fast growth in protein therapeutics will also strengthen other emerging sectors. Bio-generics will represent a key future growth segment as it will try to offset the loss of market revenue as a result of patent expirations of branded therapies. Additionally, the market trends studied in the report suggest that, a lot of research work in the segment would be targeting the immunogenicity issues related to the protein therapies.
The report provides extensive information and rational analysis of the global protein therapeutics market. It has thoroughly examined current market trends, industrial developments, and competitive landscape to enable clients understands the market structure and its progress in coming years. The forecasts presented in the report are based on the correlation between the market trends and drivers.
Multi-User License: US$ 2,800.00
Hard Copy: US$ 2,200.00
CD-ROM: US$ 2,200.00
Within the global pharmaceutical industry, protein therapeutics has been enjoying the fastest growth for the past few years. Playing a significant role in the treatment of many major diseases, protein therapies have revolutionized the methodology followed by drugs. These therapies owe their high efficiency to their targeted approach, which avoids side effects on healthy organs to a great extent. The acceptance of the various protein therapies can be attributed to the increasing prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and rising penetration of medical insurance.
According to our new research report “Global Protein Therapeutics Market Analysis”, the global protein therapeutics market is expected to grow at a CAGR of around 13% during 2012-2014. Various factors, such as introduction of new protein therapeutics and enhanced investments will contribute to the buoyant growth of this industry. Besides, augmentation in the number of clinical trials will surface the optimistic performance of the industry.
Based on our in-depth analysis of the industry, we have identified the major segments in protein therapeutics market, which include Monoclonal antibody, Insulin, Interferon, G-CSF, coagulation factors etc. Amongst the segments, monoclonal antibody dominates the global protein therapeutics market and is expected to be at the top in future as well. This has been possible due to the large numbers of players that have been directing their efforts to develop innovative treatments using mAbs.
As per our research, fast growth in protein therapeutics will also strengthen other emerging sectors. Bio-generics will represent a key future growth segment as it will try to offset the loss of market revenue as a result of patent expirations of branded therapies. Additionally, the market trends studied in the report suggest that, a lot of research work in the segment would be targeting the immunogenicity issues related to the protein therapies.
The report provides extensive information and rational analysis of the global protein therapeutics market. It has thoroughly examined current market trends, industrial developments, and competitive landscape to enable clients understands the market structure and its progress in coming years. The forecasts presented in the report are based on the correlation between the market trends and drivers.
1. ANALYST VIEW
2. GLOBAL PROTEIN THERAPEUTICS MARKET
2.1 Market Analysis
2.1.1 Market Size
2.1.2 Proteins Therapeutic Market vs Pharmaceutical Market
2.1.3 Market Segmentation
2.2 Future Outlook (2012-2014)
3. INDUSTRY PERFORMANCE
3.1 Monoclonal Antibodies (mAbs)
3.1.1 Market Size
3.1.2 By Application
3.1.3 Key Geographical Markets
3.1.4 Key Players and Drugs
3.1.5 Industry Analysis
3.1.6 Recent Developments
3.1.7 Future Outlook (2012-2014)
3.2 Erythropoietin (EPO)
3.2.1 Market Size
3.2.2 By Application
3.2.3 Key Geographical Markets
3.2.4 Key Players and Drugs
3.2.5 Industry Analysis
3.2.6 Recent Developments
3.2.7 Future Outlook (2012-2014)
3.3 Insulin
3.3.1 Market Size
3.3.2 By Application
3.3.3 Key Geographical Markets
3.3.4 Key Players and Drugs
3.3.5 Industry Analysis
3.3.6 Recent Developments
3.3.7 Future Outlook (2012-2014)
3.4 Interferon (IFN)
3.4.1 Market Size
3.4.2 Key Geographical Markets
3.4.3 Key Players and Drugs
3.4.4 Industry Analysis
3.4.5 Recent Developments
3.4.6 Future Outlook (2012-2014)
3.5 Human Growth Hormone (HGH)
3.5.1 Market Size
3.5.2 By Application
3.5.3 Key Geographical Markets
3.5.4 Key Players and Drugs
3.5.5 Industry Analysis
3.5.6 Recent Developments
3.5.7 Future Outlook (2012-2014)
3.6 Blood Clotting Factor
3.6.1 Market Size
3.6.2 Key Players and Drugs
3.6.3 Industry Analysis
3.6.4 Recent Developments
3.6.5 Future Outlook (2012-2014)
3.7 Follicle Stimulating Hormone (FSH)
3.7.1 Market Size
3.7.2 Key Players and Drugs
3.7.3 Industry Analysis
3.7.4 Future Outlook (2012-2014)
3.8 Granulocyte Colony Stimulating Factor (G-CSF)
3.8.1 Market Size
3.8.2 Key Players and Drugs
3.8.3 Industry Analysis
3.8.4 Future Outlook (2012-2014)
4. EMERGING MARKET TRENDS
4.1 Synthetic Biology: Taking Command of the Industry
4.2 Drug-like Protein Therapies: Increasing Stability
4.3 Effective Delivery Methods: Improving the Reach of Therapies
4.4 Tackling Immunogenicity Issues: Ensuring Product Safety
4.5 Multifunctional Proteins: Targeting Wider Range of Diseases
5. KEY PLAYERS
5.1 Johnson & Johnson
5.2 Biogen Idec Inc.
5.3 Eli Lilly & Company
5.4 Sanofi-Aventis
5.5 Merck Serono S.A.
5.6 Roche Group
5.7 Amgen Inc.
2. GLOBAL PROTEIN THERAPEUTICS MARKET
2.1 Market Analysis
2.1.1 Market Size
2.1.2 Proteins Therapeutic Market vs Pharmaceutical Market
2.1.3 Market Segmentation
2.2 Future Outlook (2012-2014)
3. INDUSTRY PERFORMANCE
3.1 Monoclonal Antibodies (mAbs)
3.1.1 Market Size
3.1.2 By Application
3.1.3 Key Geographical Markets
3.1.4 Key Players and Drugs
3.1.5 Industry Analysis
3.1.6 Recent Developments
3.1.7 Future Outlook (2012-2014)
3.2 Erythropoietin (EPO)
3.2.1 Market Size
3.2.2 By Application
3.2.3 Key Geographical Markets
3.2.4 Key Players and Drugs
3.2.5 Industry Analysis
3.2.6 Recent Developments
3.2.7 Future Outlook (2012-2014)
3.3 Insulin
3.3.1 Market Size
3.3.2 By Application
3.3.3 Key Geographical Markets
3.3.4 Key Players and Drugs
3.3.5 Industry Analysis
3.3.6 Recent Developments
3.3.7 Future Outlook (2012-2014)
3.4 Interferon (IFN)
3.4.1 Market Size
3.4.2 Key Geographical Markets
3.4.3 Key Players and Drugs
3.4.4 Industry Analysis
3.4.5 Recent Developments
3.4.6 Future Outlook (2012-2014)
3.5 Human Growth Hormone (HGH)
3.5.1 Market Size
3.5.2 By Application
3.5.3 Key Geographical Markets
3.5.4 Key Players and Drugs
3.5.5 Industry Analysis
3.5.6 Recent Developments
3.5.7 Future Outlook (2012-2014)
3.6 Blood Clotting Factor
3.6.1 Market Size
3.6.2 Key Players and Drugs
3.6.3 Industry Analysis
3.6.4 Recent Developments
3.6.5 Future Outlook (2012-2014)
3.7 Follicle Stimulating Hormone (FSH)
3.7.1 Market Size
3.7.2 Key Players and Drugs
3.7.3 Industry Analysis
3.7.4 Future Outlook (2012-2014)
3.8 Granulocyte Colony Stimulating Factor (G-CSF)
3.8.1 Market Size
3.8.2 Key Players and Drugs
3.8.3 Industry Analysis
3.8.4 Future Outlook (2012-2014)
4. EMERGING MARKET TRENDS
4.1 Synthetic Biology: Taking Command of the Industry
4.2 Drug-like Protein Therapies: Increasing Stability
4.3 Effective Delivery Methods: Improving the Reach of Therapies
4.4 Tackling Immunogenicity Issues: Ensuring Product Safety
4.5 Multifunctional Proteins: Targeting Wider Range of Diseases
5. KEY PLAYERS
5.1 Johnson & Johnson
5.2 Biogen Idec Inc.
5.3 Eli Lilly & Company
5.4 Sanofi-Aventis
5.5 Merck Serono S.A.
5.6 Roche Group
5.7 Amgen Inc.
LIST OF FIGURES:
Figure 2-1: Global - Protein Therapeutics Market (Billion US$), 2010 & 2011
Figure 2-2: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2010
Figure 2-3: Global - Protein Therapeutics Market by Segment (%), 2010
Figure 2-4: Global - Forecast for Protein Therapeutics Market (Billion US$), 2012-2014
Figure 2-5: Global - Forecast for Protein Therapeutics Market by Segment (%), 2014
Figure 3-1: Global - Monoclonal Antibodies Market (Billion US$), 2010 & 2011
Figure 3-2: Global - Monoclonal Antibodies Market by Segment (%), 2010
Figure 3-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2010 & 2011
Figure 3-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2010 & 2011
Figure 3-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2010 & 2011
Figure 3-6: US - Monoclonal Antibodies Market (Billion US$), 2010 & 2011
Figure 3-7: US - Forecast for Monoclonal Antibodies Market (Billion US$), 2012-2014
Figure 3-8: Europe - Monoclonal Antibodies Market (Billion US$), 2010 & 2011
Figure 3-9: Europe - Forecast for Monoclonal Antibodies Market (Billion US$), 2012-2014
Figure 3-10: Europe - Monoclonal Antibodies Market by Application (%), 2011
Figure 3-11: Japan - Monoclonal Antibodies Market (Billion US$), 2010 & 2011
Figure 3-12: Japan - Forecast for Monoclonal Antibodies Market (Billion US$), 2012-2014
Figure 3-13: Global - Share of Key Players in Monoclonal Antibodies Market (2010)
Figure 3-14: Global - Top Selling Monoclonal Antibodies (Billion US$), 2010
Figure 3-15: Global - Forecast for Monoclonal Antibodies Market (Billion US$), 2012-2014
Figure 3-16: Global - Erythropoietin Market (Billion US$), 2010 & 2011
Figure 3-17: Global - Number of Patients on Dialysis (Million), 2008-2010
Figure 3-18: Global - Breakup of Patients on Dialysis by Region (%), 2010
Figure 3-19: Global - Number of New Cancer Cases (Million), 2008 & 2030
Figure 3-20: Global - Breakup of New Cancer Cases by Region (%), 2008
Figure 3-21: Europe - Erythropoietin Market (Billion US$), 2010-2014
Figure 3-22: Europe - Erythropoietin Biosimilar Market by Country (%), 2010
Figure 3-23: Europe - First Generation Erythropoietin Patent Expiry by Major Country
Figure 3-24: Japan - Erythropoietin Market (Million US$), 2009-2011
Figure 3-25: Global - Forecast for Erythropoietin Market (Billion US$), 2012-2014
Figure 3-26: Europe - Forecast for Share of Oncology and Renal Anemia in Erythropoietin Market (2016)
Figure 3-27: Global - Insulin Market (Billion US$), 2008-2011
Figure 3-28: India - Number of Diabetic Patients (Million), 2010 & 2030
Figure 3-29: India - Insulin Market (Million US$), 2010 & 2011
Figure 3-30: India - Share of Key Players in Insulin Market (2010)
Figure 3-31: China - Insulin Market (Billion RMB), 2009-2011
Figure 3-32: China - Share of Key Players in Insulin Market (2010)
Figure 3-33: US - Insulin Market (Billion US$), 2008-2011
Figure 3-34: US - Share of Key Players in Insulin Market (2010)
Figure 3-35: Russia - Insulin Market (Million US$), 2009-2011
Figure 3-36: Russia - Share of Key Players in Insulin Market (H1 2009)
Figure 3-37: Japan - Insulin Market (Million US$), 2008-2011
Figure 3-38: Japan - Share of Key Players in Insulin Market (2009)
Figure 3-39: Germany - Share of Insulin in Genetically Manufactured Pharmaceuticals Market (2007)
Figure 3-40: Brazil - Insulin Market (Million US$), 2008-2011
Figure 3-41: Brazil - Share of Key Players in Insulin Market (2010)
Figure 3-42: Global - Share of Key Players in Insulin Market (2010)
Figure 3-43: Global - Share of Brands in Insulin Market (2010)
Figure 3-44: Global - Number of Diabetic Patients (Million), 2010 & 2030
Figure 3-45: Global - Forecast for Insulin Market (Billion US$), 2012-2014
Figure 3-46: Global - Interferon Market (Billion US$), 2008-2011
Figure 3-47: Global - Share of Alpha and Beta in Interferon Market (2010)
Figure 3-48: Global - Interferon Alpha Market (Billion US$), 2008-2010
Figure 3-49: Global - Hepatitis B Treatment Market (Billion US$), 2010-2014
Figure 3-50: Global - Hepatitis C Treatment Market (Billion US$), 2010-2014
Figure 3-51: Global - Interferon Beta Market (Billion US$), 2008-2010
Figure 3-52: Global - Multiple Sclerosis Treatment Market (Billion US$), 2008-2010
Figure 3-53: US - Interferon Market (Billion US$), 2006 & 2010
Figure 3-54: Europe - Interferon Market (Million US$)
Figure 3-55: Japan - Interferon Market (Million US$), 2007-2010
Figure 3-56: Global - Forecast for Interferon Market (Billion US$), 2012-2014
Figure 3-57: Global - Human Growth Hormone Market (Billion US$), 2008-2011
Figure 3-58: US, Europe & Japan - Number of Patients with Pediatric Growth Hormone Deficiency (‘000)
Figure 3-59: Global - Share of Growth Hormones in Treatment of Pediatric Short Stature
Figure 3-60: Global - Adult Growth Hormone Deficiency Market (Million US$)
Figure 3-61: Global - Human Growth Hormone Market by Region (%), 2009
Figure 3-62: US & Europe - Human Growth Hormone Market (Million US$), 2009
Figure 3-63: Japan - Human Growth Hormone Market (Million US$), 2007-2009
Figure 3-64: Global - Share of Key Players in Human Growth Hormone Market (2010)
Figure 3-65: Global - Forecast for Human Growth Hormone Market (Billion US$), 2012-2014
Figure 3-66: Global - Blood Clotting Factor Market (Billion US$), 2008-2011
Figure 3-67: Global - Share of Blood Clotting Factor Market by Segment (2010)
Figure 3-68: Global - Share of Key Players in Blood Clotting Factor Market (2010)
Figure 3-69: Global - Forecast for Blood Clotting Factor Market (Billion US$), 2012-2014
Figure 3-70: Global - Follicle Stimulating Hormone Market (Billion US$), 2008-2011
Figure 3-71: Global - Forecast for Follicle Stimulating Hormone Market (Billion US$), 2012-2014
Figure 3-72: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2008-2011
Figure 3-73: US - Share in Global Granulocyte Colony Stimulating Factor Market
Figure 3-74: Global - Forecast for Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2014
Figure 4-1: Global - Nanotechnology-enabled Drug Delivery Market (Billion US$), 2007 & 2012
Figure 2-1: Global - Protein Therapeutics Market (Billion US$), 2010 & 2011
Figure 2-2: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2010
Figure 2-3: Global - Protein Therapeutics Market by Segment (%), 2010
Figure 2-4: Global - Forecast for Protein Therapeutics Market (Billion US$), 2012-2014
Figure 2-5: Global - Forecast for Protein Therapeutics Market by Segment (%), 2014
Figure 3-1: Global - Monoclonal Antibodies Market (Billion US$), 2010 & 2011
Figure 3-2: Global - Monoclonal Antibodies Market by Segment (%), 2010
Figure 3-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2010 & 2011
Figure 3-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2010 & 2011
Figure 3-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2010 & 2011
Figure 3-6: US - Monoclonal Antibodies Market (Billion US$), 2010 & 2011
Figure 3-7: US - Forecast for Monoclonal Antibodies Market (Billion US$), 2012-2014
Figure 3-8: Europe - Monoclonal Antibodies Market (Billion US$), 2010 & 2011
Figure 3-9: Europe - Forecast for Monoclonal Antibodies Market (Billion US$), 2012-2014
Figure 3-10: Europe - Monoclonal Antibodies Market by Application (%), 2011
Figure 3-11: Japan - Monoclonal Antibodies Market (Billion US$), 2010 & 2011
Figure 3-12: Japan - Forecast for Monoclonal Antibodies Market (Billion US$), 2012-2014
Figure 3-13: Global - Share of Key Players in Monoclonal Antibodies Market (2010)
Figure 3-14: Global - Top Selling Monoclonal Antibodies (Billion US$), 2010
Figure 3-15: Global - Forecast for Monoclonal Antibodies Market (Billion US$), 2012-2014
Figure 3-16: Global - Erythropoietin Market (Billion US$), 2010 & 2011
Figure 3-17: Global - Number of Patients on Dialysis (Million), 2008-2010
Figure 3-18: Global - Breakup of Patients on Dialysis by Region (%), 2010
Figure 3-19: Global - Number of New Cancer Cases (Million), 2008 & 2030
Figure 3-20: Global - Breakup of New Cancer Cases by Region (%), 2008
Figure 3-21: Europe - Erythropoietin Market (Billion US$), 2010-2014
Figure 3-22: Europe - Erythropoietin Biosimilar Market by Country (%), 2010
Figure 3-23: Europe - First Generation Erythropoietin Patent Expiry by Major Country
Figure 3-24: Japan - Erythropoietin Market (Million US$), 2009-2011
Figure 3-25: Global - Forecast for Erythropoietin Market (Billion US$), 2012-2014
Figure 3-26: Europe - Forecast for Share of Oncology and Renal Anemia in Erythropoietin Market (2016)
Figure 3-27: Global - Insulin Market (Billion US$), 2008-2011
Figure 3-28: India - Number of Diabetic Patients (Million), 2010 & 2030
Figure 3-29: India - Insulin Market (Million US$), 2010 & 2011
Figure 3-30: India - Share of Key Players in Insulin Market (2010)
Figure 3-31: China - Insulin Market (Billion RMB), 2009-2011
Figure 3-32: China - Share of Key Players in Insulin Market (2010)
Figure 3-33: US - Insulin Market (Billion US$), 2008-2011
Figure 3-34: US - Share of Key Players in Insulin Market (2010)
Figure 3-35: Russia - Insulin Market (Million US$), 2009-2011
Figure 3-36: Russia - Share of Key Players in Insulin Market (H1 2009)
Figure 3-37: Japan - Insulin Market (Million US$), 2008-2011
Figure 3-38: Japan - Share of Key Players in Insulin Market (2009)
Figure 3-39: Germany - Share of Insulin in Genetically Manufactured Pharmaceuticals Market (2007)
Figure 3-40: Brazil - Insulin Market (Million US$), 2008-2011
Figure 3-41: Brazil - Share of Key Players in Insulin Market (2010)
Figure 3-42: Global - Share of Key Players in Insulin Market (2010)
Figure 3-43: Global - Share of Brands in Insulin Market (2010)
Figure 3-44: Global - Number of Diabetic Patients (Million), 2010 & 2030
Figure 3-45: Global - Forecast for Insulin Market (Billion US$), 2012-2014
Figure 3-46: Global - Interferon Market (Billion US$), 2008-2011
Figure 3-47: Global - Share of Alpha and Beta in Interferon Market (2010)
Figure 3-48: Global - Interferon Alpha Market (Billion US$), 2008-2010
Figure 3-49: Global - Hepatitis B Treatment Market (Billion US$), 2010-2014
Figure 3-50: Global - Hepatitis C Treatment Market (Billion US$), 2010-2014
Figure 3-51: Global - Interferon Beta Market (Billion US$), 2008-2010
Figure 3-52: Global - Multiple Sclerosis Treatment Market (Billion US$), 2008-2010
Figure 3-53: US - Interferon Market (Billion US$), 2006 & 2010
Figure 3-54: Europe - Interferon Market (Million US$)
Figure 3-55: Japan - Interferon Market (Million US$), 2007-2010
Figure 3-56: Global - Forecast for Interferon Market (Billion US$), 2012-2014
Figure 3-57: Global - Human Growth Hormone Market (Billion US$), 2008-2011
Figure 3-58: US, Europe & Japan - Number of Patients with Pediatric Growth Hormone Deficiency (‘000)
Figure 3-59: Global - Share of Growth Hormones in Treatment of Pediatric Short Stature
Figure 3-60: Global - Adult Growth Hormone Deficiency Market (Million US$)
Figure 3-61: Global - Human Growth Hormone Market by Region (%), 2009
Figure 3-62: US & Europe - Human Growth Hormone Market (Million US$), 2009
Figure 3-63: Japan - Human Growth Hormone Market (Million US$), 2007-2009
Figure 3-64: Global - Share of Key Players in Human Growth Hormone Market (2010)
Figure 3-65: Global - Forecast for Human Growth Hormone Market (Billion US$), 2012-2014
Figure 3-66: Global - Blood Clotting Factor Market (Billion US$), 2008-2011
Figure 3-67: Global - Share of Blood Clotting Factor Market by Segment (2010)
Figure 3-68: Global - Share of Key Players in Blood Clotting Factor Market (2010)
Figure 3-69: Global - Forecast for Blood Clotting Factor Market (Billion US$), 2012-2014
Figure 3-70: Global - Follicle Stimulating Hormone Market (Billion US$), 2008-2011
Figure 3-71: Global - Forecast for Follicle Stimulating Hormone Market (Billion US$), 2012-2014
Figure 3-72: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2008-2011
Figure 3-73: US - Share in Global Granulocyte Colony Stimulating Factor Market
Figure 3-74: Global - Forecast for Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2014
Figure 4-1: Global - Nanotechnology-enabled Drug Delivery Market (Billion US$), 2007 & 2012
LIST OF TABLES:
Table 3-1: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2010
Table 3-2: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2010
Table 3-3: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2010
Table 3-4: China - Diabetic Patients in Age Group 20-79 Years (‘000), 2010 & 2030
Table 3-5: US - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-6: Russia - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-7: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-8: Germany - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-9: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-10: Global - Key Players and Drugs in Interferon Alpha Market (Million US$), 2010
Table 3-11: Global - Key Players and Drugs in Interferon Beta Market (Million US$), 2010
Table 3-12: Global - Key Players and Drugs in Human Growth Hormone Market (Million US$), 2010
Table 3-13: Global - Key Players and Drugs in Blood Clotting Factor Market (Million US$), 2010
Table 3-14: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Million US$), 2010
Table 3-15: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Million US$), 2010
Table 3-1: Global - Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2010
Table 3-2: Global - Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2010
Table 3-3: Global - Key Players and Drugs in Darbepoetin Market (Million US$), 2010
Table 3-4: China - Diabetic Patients in Age Group 20-79 Years (‘000), 2010 & 2030
Table 3-5: US - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-6: Russia - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-7: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-8: Germany - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-9: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2010 & 2030
Table 3-10: Global - Key Players and Drugs in Interferon Alpha Market (Million US$), 2010
Table 3-11: Global - Key Players and Drugs in Interferon Beta Market (Million US$), 2010
Table 3-12: Global - Key Players and Drugs in Human Growth Hormone Market (Million US$), 2010
Table 3-13: Global - Key Players and Drugs in Blood Clotting Factor Market (Million US$), 2010
Table 3-14: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Million US$), 2010
Table 3-15: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Million US$), 2010
